Abstract
The currently available thrombolytic agents are widely perceived to be suboptimal in terms of both efficacy and safety. This perception has in turn stimulated efforts to design and construct novel plasminogen activators endowed with improved biochemical and pharmacologic properties. There is as yet no consensus as to the properties of an "ideal" thrombolytic agent, and the failure of comparative clinical trials to identify a superior agent has contributed to the controversy. Although an improved plasminogen activator has not yet been constructed, it is clear that efforts to do so have advanced our knowledge of the complex structure-function relationships within plasminogen activators.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 36-39 |
| Number of pages | 4 |
| Journal | Trends in Cardiovascular Medicine |
| Volume | 1 |
| Issue number | 1 |
| DOIs | |
| State | Published - 1991 |
Funding
This work was supported by grants HL40411 and HL43344 from the Na tional Institutes of Health . Douglas E . Vaughan is the recipient of a Clinician-Scientist Award from the American Heart Association, Dallas, Texas, and a Research Advisory Group Award from the Veterans Administration . Joseph Loscalzo is the recipient of a Research Career Development Award (K04HL02273) from the National Institutes of Health and a Research Advisory Group Award from the Veterans Administration . The authors wish to thank Ms . S . Tribuna for excellent secretarial support .
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine